Multi-modal measurement of the longitudinal effects of classic psychedelic drugs in psychiatric, neurological, and healthy populations
This project will add biological, psychological, and social data collection to multiple ongoing clinical trials studying psilocybin. By gathering data across a wide range of mental and behavioral health conditions (e.g., depression, opioid use disorder, PTSD), the effort aims to create a large, scalable resource that can support broader discovery and more generalizable insights. Data and biological samples collected under this award will be deidentified and housed in the ARPA-H EVIDENT Data and Biorepositories.